
After lymphoma returned in his brain, one cancer survivor reflects on hospice, mortality, family, jealousy and gratitude for the life he was able to live.

After lymphoma returned in his brain, one cancer survivor reflects on hospice, mortality, family, jealousy and gratitude for the life he was able to live.

See how FDA-approved lymphoma treatments have changed over 5 years — what's new, who it's helped, and what's still to come.

Kazia Therapeutics CEO Dr. John Friend discussed how paxalisib is being studied in HR-positive, HER2-negative breast cancer, why researchers are focusing on treatment resistance and what the ongoing clinical trial could show for patients.

An expert discusses August's FDA approvals for myeloma, polycythemia vera and essential thrombocythemia, plus first-line myeloma care and MRD testing.

Patients with colorectal cancer who walked more had less fatigue and better quality of life, regardless of how active they were at diagnosis.

CURE spoke with Oncology Aesthetics & Wellness founder, Deborah A. McDowell, about hair preservation before, during and after cancer treatment.

A genomic test led physicians to change extended endocrine therapy recommendations for 42% of people with early-stage HR-positive breast cancer.

A wife reflects on her husband’s cancer treatment, finding comfort, hope and connection in their simple ritual of sharing bagels before each treatment.

Survivors and experts share what to do before your first chemo infusion, from scalp cooling and saving your hair to skin care and building a support team.

After two relapses of acute lymphoblastic leukemia, Hannah Koepsell received CAR-T cell therapy. A pediatric oncologist explains why leukemia can return after treatment and how researchers are working to make CAR-T responses last longer.

FDA approves Welireg plus Lenvima for advanced clear cell kidney cancer after PD-1 or PD-L1 treatment, offering a new treatment option.

These seven breast cancer clinical trials are recruiting patients now, spanning early-stage, HR-positive, HER2-positive and triple-negative disease.

Two sisters discover they share a BRCA2 mutation, but choose different paths to manage their breast cancer risk and navigate life as previvors.

After 18 years with multiple myeloma, Sally Kalksma shares 10 people, places and things that helped her stay strong through cancer treatment.

In the latest installment of CURE's "Text a Survivor" series, Brad Moore answers some of the most common questions people have about living with and beyond a colorectal cancer diagnosis.

Lyrfigtu was approved for adults with previously treated cholangiocarcinoma with an FGFR2 gene fusion or other rearrangement.

Researchers are studying whether combining CAR-T cell therapy with targeted drugs could help children with high-risk leukemia, including infants whose cancer may be more likely to return after treatment.

Mindfulness-based cancer recovery and Tai Chi/Qigong improved fatigue and how much pain interfered with daily life among cancer survivors experiencing distress, while Tai Chi/Qigong also improved sleep quality.

A breast cancer survivor reflects on the complicated meaning of pink, remembering what cancer took, those still fighting and the people behind the ribbon.

Paxalisib, first studied in brain cancer, may help HR+ breast tumors respond to CDK4/6 inhibitors again, based on early lab data.

A cancer survivor shares what to say, what not to say and how listening can help support someone through cancer treatment and beyond.

Bravnetsa is the first radioligand therapy approved through the FDA's abbreviated pathway, adding an option for adults with SSTR-positive GEP-NETs.

The investigational drug, first developed for brain cancer, is being tested to see whether it can make resistant tumors respond to treatment again.

Cancer research is increasingly looking beyond the tumor to understand the whole body, immune system and patient experience.

AI is becoming a growing part of cancer care. Learn how doctors are using it to navigate complex treatment decisions and support patients.

In patients with advanced ROS1-positive lung cancer who had not previously received a ROS1-targeted drug, Jideytro also shrank tumors that had spread to the brain in all 10 evaluable patients.

An estimated 70% of patients with stage 3 lung cancer do not see their tumors respond to standard treatment. An expert explains why, and what a new approach aims to change.

Living with stage IV kidney cancer for 10 years, one survivor shares how he manages scanxiety, uncertainty and the waiting between scans.

After facing multiple cancers and hospice care, April Floyd credits her service dog Onyx with helping her find comfort, strength and hope.

Updated NCCN guidelines for multiple myeloma add dedicated recommendations for MRD testing, prefer tests that can detect one cancer cell among 1 million cells and expand when testing should occur.